Table 3.

%CD4+ expressing IL4, IL2, IL10 and IFN-γafter receiving 2 doses of vaccines.

	%CD4+ (95% confidence interval)
Productsa	IL2	IL4b	Aveage rank† (Overall 15.5)	IL10	Aveage rank† (Overall 15.5)	IFN-γ	Aveage rank† (Overall 15.5)
Vi-DT (AlPO)	ND	53.4 ± 7.86	17.6	74.5 ± 19.7	17.4	91.4 ± 8.66	23.2
Vi-DT (AlOH)	0.68 ± 1.00	56.1 ± 7.86	20.2	88.5 ± 19.7	24.0	88.0 ± 8.66	18,8
Vi-DT (PBS)	1.39 ± 2.77	44,5 ± 10.4	10.4	71.6 ± 12.9	17.6	62,3 ± 18.9	7.4
Vi-TT (AlPO)	0.93 ± 1.00	49.1 ± 6.79	14.2	56.2 ± 11.2	8.3	90.6 ± 9.84	21.8
Vi-TT (AlOH)	1.43 ± 1.00	65.6 ± 9.25	26.4	56.2 ± 11.2	8.3	82.6 ± 7.23	15.8
Vi-TT (PBS)	0.38 ± 2.72	34.5 ± 2.83	4.2	71.2 ± 10.9	17.4	66.8 ± 0.50	6.0

^†Test was done using Kruskal-Wallis test.

^aVi-DT (AlPO) : Vi conjugated with Diphtheria Toxoid and added adjuvant Aluminum phosphate in the final product;

Vi-DT (AlOH) : Vi conjugated with Diphtheria Toxoid and added adjuvant Aluminum hydroxide in the final product;

Vi-DT (PBS) : Vi conjugated with Diphtheria Toxoid and added Phosphate Buffer Saline in the final product;

Vi-TT (AlPO) : Vi conjugated with Tetanus Toxoid and added adjuvant Aluminum phosphate in the final product;

Vi-TT (AlOH) : Vi conjugated with Tetanus Toxoid and added adjuvant Aluminum hydroxide in the final product;

Vi-TT (PBS) : Vi conjugated with Tetanus Toxoid and added Phosphate Buffer Saline in the final product;

ND : Not Determined.

^bIL-4 : Interleukin 4;

IL-2 : Interleukin 2;

IL-10 : Interleukin 10;

IFN-γ : Interferon Gamma.